Sunday, April 13, 2025 5:32:30 PM
Thanks for sharing your perspective on the influence of the JAMA Oncology peer review. I would add that Dr. Ashkan also has considerable influence with the MHRA—his work is world-renowned and he is highly respected, especially in the UK. He led the P3 trial in Europe and currently oversees the ongoing Specials Program for DCVax-L in the UK. The MHRA continues to support the use of DCVax-L under the Specials Program, and a patient treated through the program was the subject of a peer-reviewed case study.
In April 2025, NICE published a note referencing its ongoing communication with NWBO as they are awaiting completion of MHRA’s review of their voluminous MAA submission:
“NICE is continuing to liaise with Northwest Biotherapeutics. The company reports that it is still fully occupied and engaged in the Marketing Authorisation Application (MAA) process with the MHRA.”
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143
King’s College London maintains established connections with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and Dr. Ashkan holds a prominent position at King’s!
“His work on brain cancer vaccines received the top presentation award by the British Neuro-Oncology Society in 2022 and promises to impact the care of patients with brain tumours worldwide.”
Consultant Neurosurgeon at @KingsCollegeNHS, Professor Keyoumars Ashkan, receives an MBE for services to neurosurgery.
— NHS London (@NHSEnglandLDN) December 31, 2024
In 2020, he removed patient Dagmar's brain tumour while she played her violin throughout the surgery. 👇pic.twitter.com/H2Z4LZic0h
https://thejns.org/caselessons/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.xml
https://www.kcl.ac.uk/news/professor-keyoumars-ashkan-awarded-mbe-in-kings-new-years-honours
https://www.bbc.com/news/uk-england-london-66378288
https://www.kch.nhs.uk/news/kings-team-wins-professional-excellence-award/
Congratulations to all the nominees and winners @TheSun Who Cares Wins awards, including Professor Keyoumars Ashkan, Consultant Neurosurgeon at King’s, who was a runner up in the Groundbreaking Pioneer category.#TeamKings @KensingtonRoyal @OfficialTM_3 @KingsNeuro pic.twitter.com/6qTnOfazAN
— King's College NHS (@KingsCollegeNHS) September 20, 2021
Congratulations to Professor Keyoumars Ashkan, a professor of neurosurgery at King's, who has been named UK Clinician of the Year by the @BrainTumourOrg. Find out more here: https://t.co/32b69Plheq #TeamKings pic.twitter.com/9no1BsnNqo
— King's College NHS (@KingsCollegeNHS) April 27, 2018
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
